{"id":935750,"date":"2026-02-10T16:20:13","date_gmt":"2026-02-10T21:20:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/transdermal-gfr-article-recognized-as-one-of-five-2025-editors-choice-articles-by-journal-of-the-american-society-of-nephrology-jasn\/"},"modified":"2026-02-10T16:20:13","modified_gmt":"2026-02-10T21:20:13","slug":"transdermal-gfr-article-recognized-as-one-of-five-2025-editors-choice-articles-by-journal-of-the-american-society-of-nephrology-jasn","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/transdermal-gfr-article-recognized-as-one-of-five-2025-editors-choice-articles-by-journal-of-the-american-society-of-nephrology-jasn\/","title":{"rendered":"Transdermal GFR Article Recognized as One of Five 2025 Editors\u2019 Choice Articles by Journal of the American Society of Nephrology (JASN)"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li>\n          <strong>MediBeacon<\/strong><br \/>\n          <sup><br \/>\n            <strong>\u00ae <\/strong><br \/>\n          <\/sup><br \/>\n          <strong>Transdermal GFR System is a first-in-kind product for point of care kidney function assessment<\/strong>\n        <\/li>\n<li>\n          <strong>Centers of Excellence commercialization in select academic medical centers began in January 2026<\/strong>\n        <\/li>\n<\/ul>\n<p align=\"justify\">NEW YORK, Feb.  10, 2026  (GLOBE NEWSWIRE) &#8212; INNOVATE Corp. (NYSE: VATE) (\u201cINNOVATE\u201d or the \u201cCompany\u201d) announced today that <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=m__I_CtD9WhOo3HQo2Ayx3abtuoDONfa9Cg7WNsVBfidQCyQyjtR9ZBUJtEqitz4-pbViaXWCxmV43tzTiNSlsCzo1MSQvqg09YqzQkqnUk=\" rel=\"nofollow\" target=\"_blank\">MediBeacon Inc.<\/a> (\u201cMediBeacon\u201d), a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, in which INNOVATE owns a 44.7% equity interest, announced that the peer-reviewed transdermal GFR measurement article published in the Journal of the American Society of Nephrology (JASN) has been recognized as one of five 2025 Editor\u2019s Choice articles.<sup>1<\/sup><\/p>\n<p align=\"justify\">The JASN editorial team selects five top articles each year which exemplify the highest potential to inform future research, change clinical practice, and\/or guide public policy, particularly in the United States. The article was featured on the cover of the Journal of the American Society of Nephrology (JASN) in August 2025.<sup>2<\/sup><\/p>\n<p align=\"justify\">The TGFR<strong>\u2122<\/strong> System is comprised of Lumitrace<sup><strong>\u00ae<\/strong><\/sup> (relmapirazin) injection, the TGFR<strong>\u2122<\/strong> Monitor and TGFR<strong>\u2122<\/strong> Reusable Sensor and enables the assessment of kidney function by measuring the clearance rate of the fluorescent agent as it leaves the body. The result is a transdermal assessment of Glomerular Filtration Rate or kidney function (tGFR).<\/p>\n<p align=\"justify\">\u201cThere is an acute need for improved GFR assessment at the point of care. Assessing the impact of physiologic changes or diseases on GFR in is of high potential clinical value. The limitations of estimated GFR (eGFR) are well known and existing measured GFR (mGFR) methodologies are not well suited to general clinical practice,\u201d said Dr. Steve Miller, Chief Medical Officer for MediBeacon. \u201cMany of the top institutions view transdermal GFR (tGFR) as a potential clinical practice game changer targeting a new standard of care for patients in numerous cases where the understanding of kidney function is fundamental.\u201d<\/p>\n<p align=\"justify\">\u201cWe are excited about this recognition by American Society of Nephrology,\u201d said Steven Hanley, CEO and Co-Founder of MediBeacon. \u201cOur deployment of the TGFR System across key centers of excellence initially targets use in heart failure monitoring, transplant evaluation and oncology drug dosing. Our collaboration with the top hospitals globally demonstrates this focus to strategically drive early commercial adoption of our technology where it can rapidly be demonstrated to have high clinical value.\u201d<\/p>\n<p align=\"justify\">\n        <strong>About INNOVATE<\/strong><br \/>\n        <br \/>INNOVATE Corp. is a portfolio of best-in-class assets in three key areas of the new economy \u2013 Infrastructure, Life Sciences and Spectrum. Dedicated to stakeholder capitalism, INNOVATE employs approximately 3,100 people across its subsidiaries. For more information, please visit: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gMUZcgBfOgfXKsOFKZ4RFrBtcsH61rbSUf9CfUp-AqYjJElX0waQjTe-6olP2KO6r473ovi_wRc0SGpLbegXDF2Ss62930VgyE6I8uN2P9D0Gp0QgqhsAd2xNnabD43c\" rel=\"nofollow\" target=\"_blank\">http:\/\/www.innovatecorp.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About MediBeacon Inc<\/strong>.<br \/>MediBeacon is a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection. MediBeacon\u2019s use of proprietary fluorescent tracer agents coupled with transdermal detection technology focuses on providing vital and actionable measurement of organ function. MediBeacon owns over 55 granted U.S. patents and over 250 granted patents worldwide that provide extensive coverage of the MediBeacon<sup>\u00ae<\/sup> TGFR\u2122 System, including Lumitrace<sup>\u00ae<\/sup> injection, the sensor and algorithms, as well as other strategic uses of its proprietary pyrazine platform and sensor technology. The TGFR System is approved for human use. Potential technology applications in gastroenterology, ophthalmology and surgery are in various stages of clinical development. MediBeacon is based in St. Louis, Missouri, with additional operations in Mannheim, Germany. For more information, please visit: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=V5At7ucspuyWO4_6N3RkUQXjcZavjDfwmQmaGk10aDvsoJmV7yuHOIJrzX-BTqKU9owEVBS8Ay9hxmegcQyMoSTt6HvU_p74ASy-u7HYu9I=\" rel=\"nofollow\" target=\"_blank\">www.medibeacon.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Lumitrace<\/strong><br \/>\n        <sup><br \/>\n          <strong>\u00ae<\/strong><br \/>\n        <\/sup><br \/>\n        <strong> (relmapirazin) injection<\/strong><br \/>\n        <br \/>Relmapirazin is a non-radioactive, non-iodinated pyrazine-based compound, which has been engineered to be inert, highly fluorescent, and have the clearance properties of a GFR tracer agent in the body. The unique photophysical characteristics of Lumitrace have been designed to enable the collection of fluorescence data via a photodetector sensor placed on the skin. Data collected by the sensor measures the change in the intensity of Lumitrace fluorescence over time and is converted into a transdermal GFR (tGFR) by proprietary algorithms. In a phase 2 investigational study mGFR deduced from Lumitrace matched that of mGFR deduced from iohexol over a range of GFR values. See the peer reviewed article published in the October 2024 issue of Kidney International by Dorshow et al.<sup>3<\/sup><\/p>\n<p align=\"justify\">\n        <strong>About MediBeacon<\/strong><br \/>\n        <sup><br \/>\n          <strong>\u00ae<\/strong><br \/>\n        <\/sup><br \/>\n        <strong> TGFR\u2122 System<\/strong><br \/>\n        <br \/>The MediBeacon<sup><strong>\u00ae<\/strong><\/sup> TGFR<strong>\u2122<\/strong> System is comprised of the TGFR<strong>\u2122<\/strong> Reusable Sensor, TGFR<strong>\u2122<\/strong> Monitor, TGFR<strong>\u2122<\/strong> Disposable Ring, and Lumitrace<sup>\u00ae<\/sup> (relmapirazin) injection, which together allow assessment of kidney function by measuring the clearance rate of the fluorescent agent as it leaves the body. The system records Lumitrace fluorescence intensity transdermally as a function of time via a sensor placed on the skin. The TGFR Reusable Sensor records 2.5 fluorescent readings per second and the TGFR Monitor will display the average session tGFR reading at the point of care.<\/p>\n<p align=\"justify\">FOR IMPORTANT SAFETY INFORMATION FOR THE TGFR SYSTEM (U.S. FDA) see <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cZ6hlU6ltYDWprKubFmQ2rGvhx02DUN-Spgo39JoNyEnRUhyU1gqMBJI2VXWXmyQRJOQZFGZXF-Yl50expZFMbSQkqwDJcKY0t42TJqxKmk=\" rel=\"nofollow\" target=\"_blank\">ifu.medibeacon.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<br \/><\/strong>Certain statements in this press release may constitute \u201cforward-looking statements\u201d within the meaning of the federal securities laws. Forward-looking statements generally relate to future events, including, but not limited to, statements regarding the market for the TGFR<strong>\u2122<\/strong>. You are cautioned that such statements are not guarantees of future performance and that INNOVATE\u2019s actual results may differ materially from those set forth in the forward-looking statements. All of these forward-looking statements are subject to risks and uncertainties that may change at any time. Factors that could cause INNOVATE\u2019s actual expectations to differ materially from these forward-looking statements include risks associated with managing growth related to increased operational size, the misuse by customers, physicians and technicians of MediBeacon\u2019s products, and the ability of MediBeacon to effectively protect its intellectual property and the impact of a failure to do so and the other factors under the heading \u201cRisk Factors\u201d set forth in INNOVATE\u2019s Annual Report on Form 10-K, as supplemented by INNOVATE\u2019s quarterly reports on Form 10-Q. Such filings are available on our website or at www.sec.gov. You should not place undue reliance on these forward-looking statements, which are made only as of the date of this press release. INNOVATE undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent developments, events, or circumstances, except as may be required under applicable securities laws.<\/p>\n<p align=\"justify\">\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Solebury Strategic Communications<br \/>Anthony Rozmus<br \/>(212) 235-2691<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gYjeL9k67z4OKjkJeQCtgAobhgE2X_ymhpd6W0jBTPZJeyA9-S3k8MrGDhipWz5JbQKPAWNBl9K_wJai8exsjgoM1Rmn2j4qMzQ-gYWivFo=\" rel=\"nofollow\" target=\"_blank\">ir@innovatecorp.com<\/a><\/p>\n<p align=\"justify\">\n        <sup>1<\/sup> https:\/\/journals.lww.com\/jasn\/Pages\/JASN_Recognizes.aspx#EditorsChoiceArticles<br \/><sup>2<\/sup> Glomerular Filtrate Rate Measurement Utilizing Transdermal Detection Methodology; Dorshow, Richard B., Debreczeny, Martin P.; Goldstein, Stuart L.; Journal of the American Society of Nephrology, 36(8):p 1592-1602, August 2025. DOI: 10.1681\/ASN 0000000639<br \/><sup>3<\/sup> Clinical validation of the novel fluorescent glomerular filtration rate tracer agent relmapirazin (MB-102), Kidney International, Volume 106, Issue 4, P679-687, October 2024, DOI: 10.1016\/j.kint.2024.06.012<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MjIwOCM3NDE4NDM3IzIwMTk4MTU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YmY3YjE4ZGUtM2YyYy00ZjkxLWI3YjAtYjdlOWVlYWExZDA5LTEwMzEzODctMjAyNi0wMi0xMC1lbg==\/tiny\/INNOVATE-Corp-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MediBeacon \u00ae Transdermal GFR System is a first-in-kind product for point of care kidney function assessment Centers of Excellence commercialization in select academic medical centers began in January 2026 NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) &#8212; INNOVATE Corp. (NYSE: VATE) (\u201cINNOVATE\u201d or the \u201cCompany\u201d) announced today that MediBeacon Inc. (\u201cMediBeacon\u201d), a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, in which INNOVATE owns a 44.7% equity interest, announced that the peer-reviewed transdermal GFR measurement article published in the Journal of the American Society of Nephrology (JASN) has been recognized as one of five 2025 Editor\u2019s Choice articles.1 The JASN editorial team selects five top articles each year which exemplify the highest potential &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/transdermal-gfr-article-recognized-as-one-of-five-2025-editors-choice-articles-by-journal-of-the-american-society-of-nephrology-jasn\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Transdermal GFR Article Recognized as One of Five 2025 Editors\u2019 Choice Articles by Journal of the American Society of Nephrology (JASN)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-935750","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Transdermal GFR Article Recognized as One of Five 2025 Editors\u2019 Choice Articles by Journal of the American Society of Nephrology (JASN) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/transdermal-gfr-article-recognized-as-one-of-five-2025-editors-choice-articles-by-journal-of-the-american-society-of-nephrology-jasn\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Transdermal GFR Article Recognized as One of Five 2025 Editors\u2019 Choice Articles by Journal of the American Society of Nephrology (JASN) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MediBeacon \u00ae Transdermal GFR System is a first-in-kind product for point of care kidney function assessment Centers of Excellence commercialization in select academic medical centers began in January 2026 NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) &#8212; INNOVATE Corp. (NYSE: VATE) (\u201cINNOVATE\u201d or the \u201cCompany\u201d) announced today that MediBeacon Inc. (\u201cMediBeacon\u201d), a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, in which INNOVATE owns a 44.7% equity interest, announced that the peer-reviewed transdermal GFR measurement article published in the Journal of the American Society of Nephrology (JASN) has been recognized as one of five 2025 Editor\u2019s Choice articles.1 The JASN editorial team selects five top articles each year which exemplify the highest potential &hellip; Continue reading &quot;Transdermal GFR Article Recognized as One of Five 2025 Editors\u2019 Choice Articles by Journal of the American Society of Nephrology (JASN)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/transdermal-gfr-article-recognized-as-one-of-five-2025-editors-choice-articles-by-journal-of-the-american-society-of-nephrology-jasn\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-10T21:20:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MjIwOCM3NDE4NDM3IzIwMTk4MTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transdermal-gfr-article-recognized-as-one-of-five-2025-editors-choice-articles-by-journal-of-the-american-society-of-nephrology-jasn\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transdermal-gfr-article-recognized-as-one-of-five-2025-editors-choice-articles-by-journal-of-the-american-society-of-nephrology-jasn\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Transdermal GFR Article Recognized as One of Five 2025 Editors\u2019 Choice Articles by Journal of the American Society of Nephrology (JASN)\",\"datePublished\":\"2026-02-10T21:20:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transdermal-gfr-article-recognized-as-one-of-five-2025-editors-choice-articles-by-journal-of-the-american-society-of-nephrology-jasn\\\/\"},\"wordCount\":1098,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transdermal-gfr-article-recognized-as-one-of-five-2025-editors-choice-articles-by-journal-of-the-american-society-of-nephrology-jasn\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MjIwOCM3NDE4NDM3IzIwMTk4MTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transdermal-gfr-article-recognized-as-one-of-five-2025-editors-choice-articles-by-journal-of-the-american-society-of-nephrology-jasn\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transdermal-gfr-article-recognized-as-one-of-five-2025-editors-choice-articles-by-journal-of-the-american-society-of-nephrology-jasn\\\/\",\"name\":\"Transdermal GFR Article Recognized as One of Five 2025 Editors\u2019 Choice Articles by Journal of the American Society of Nephrology (JASN) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transdermal-gfr-article-recognized-as-one-of-five-2025-editors-choice-articles-by-journal-of-the-american-society-of-nephrology-jasn\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transdermal-gfr-article-recognized-as-one-of-five-2025-editors-choice-articles-by-journal-of-the-american-society-of-nephrology-jasn\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MjIwOCM3NDE4NDM3IzIwMTk4MTU=\",\"datePublished\":\"2026-02-10T21:20:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transdermal-gfr-article-recognized-as-one-of-five-2025-editors-choice-articles-by-journal-of-the-american-society-of-nephrology-jasn\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transdermal-gfr-article-recognized-as-one-of-five-2025-editors-choice-articles-by-journal-of-the-american-society-of-nephrology-jasn\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transdermal-gfr-article-recognized-as-one-of-five-2025-editors-choice-articles-by-journal-of-the-american-society-of-nephrology-jasn\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MjIwOCM3NDE4NDM3IzIwMTk4MTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MjIwOCM3NDE4NDM3IzIwMTk4MTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transdermal-gfr-article-recognized-as-one-of-five-2025-editors-choice-articles-by-journal-of-the-american-society-of-nephrology-jasn\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Transdermal GFR Article Recognized as One of Five 2025 Editors\u2019 Choice Articles by Journal of the American Society of Nephrology (JASN)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Transdermal GFR Article Recognized as One of Five 2025 Editors\u2019 Choice Articles by Journal of the American Society of Nephrology (JASN) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/transdermal-gfr-article-recognized-as-one-of-five-2025-editors-choice-articles-by-journal-of-the-american-society-of-nephrology-jasn\/","og_locale":"en_US","og_type":"article","og_title":"Transdermal GFR Article Recognized as One of Five 2025 Editors\u2019 Choice Articles by Journal of the American Society of Nephrology (JASN) - Market Newsdesk","og_description":"MediBeacon \u00ae Transdermal GFR System is a first-in-kind product for point of care kidney function assessment Centers of Excellence commercialization in select academic medical centers began in January 2026 NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) &#8212; INNOVATE Corp. (NYSE: VATE) (\u201cINNOVATE\u201d or the \u201cCompany\u201d) announced today that MediBeacon Inc. (\u201cMediBeacon\u201d), a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, in which INNOVATE owns a 44.7% equity interest, announced that the peer-reviewed transdermal GFR measurement article published in the Journal of the American Society of Nephrology (JASN) has been recognized as one of five 2025 Editor\u2019s Choice articles.1 The JASN editorial team selects five top articles each year which exemplify the highest potential &hellip; Continue reading \"Transdermal GFR Article Recognized as One of Five 2025 Editors\u2019 Choice Articles by Journal of the American Society of Nephrology (JASN)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/transdermal-gfr-article-recognized-as-one-of-five-2025-editors-choice-articles-by-journal-of-the-american-society-of-nephrology-jasn\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-10T21:20:13+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MjIwOCM3NDE4NDM3IzIwMTk4MTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/transdermal-gfr-article-recognized-as-one-of-five-2025-editors-choice-articles-by-journal-of-the-american-society-of-nephrology-jasn\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/transdermal-gfr-article-recognized-as-one-of-five-2025-editors-choice-articles-by-journal-of-the-american-society-of-nephrology-jasn\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Transdermal GFR Article Recognized as One of Five 2025 Editors\u2019 Choice Articles by Journal of the American Society of Nephrology (JASN)","datePublished":"2026-02-10T21:20:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/transdermal-gfr-article-recognized-as-one-of-five-2025-editors-choice-articles-by-journal-of-the-american-society-of-nephrology-jasn\/"},"wordCount":1098,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/transdermal-gfr-article-recognized-as-one-of-five-2025-editors-choice-articles-by-journal-of-the-american-society-of-nephrology-jasn\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MjIwOCM3NDE4NDM3IzIwMTk4MTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/transdermal-gfr-article-recognized-as-one-of-five-2025-editors-choice-articles-by-journal-of-the-american-society-of-nephrology-jasn\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/transdermal-gfr-article-recognized-as-one-of-five-2025-editors-choice-articles-by-journal-of-the-american-society-of-nephrology-jasn\/","name":"Transdermal GFR Article Recognized as One of Five 2025 Editors\u2019 Choice Articles by Journal of the American Society of Nephrology (JASN) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/transdermal-gfr-article-recognized-as-one-of-five-2025-editors-choice-articles-by-journal-of-the-american-society-of-nephrology-jasn\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/transdermal-gfr-article-recognized-as-one-of-five-2025-editors-choice-articles-by-journal-of-the-american-society-of-nephrology-jasn\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MjIwOCM3NDE4NDM3IzIwMTk4MTU=","datePublished":"2026-02-10T21:20:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/transdermal-gfr-article-recognized-as-one-of-five-2025-editors-choice-articles-by-journal-of-the-american-society-of-nephrology-jasn\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/transdermal-gfr-article-recognized-as-one-of-five-2025-editors-choice-articles-by-journal-of-the-american-society-of-nephrology-jasn\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/transdermal-gfr-article-recognized-as-one-of-five-2025-editors-choice-articles-by-journal-of-the-american-society-of-nephrology-jasn\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MjIwOCM3NDE4NDM3IzIwMTk4MTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MjIwOCM3NDE4NDM3IzIwMTk4MTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/transdermal-gfr-article-recognized-as-one-of-five-2025-editors-choice-articles-by-journal-of-the-american-society-of-nephrology-jasn\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Transdermal GFR Article Recognized as One of Five 2025 Editors\u2019 Choice Articles by Journal of the American Society of Nephrology (JASN)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/935750","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=935750"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/935750\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=935750"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=935750"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=935750"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}